ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 120 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $69,183 | -74.2% | 16,915 | -0.6% | 0.00% | -70.0% |
| Q1 2024 | $268,126 | +4.6% | 17,013 | +0.6% | 0.01% | 0.0% |
| Q4 2023 | $256,263 | -24.5% | 16,915 | 0.0% | 0.01% | -33.3% |
| Q3 2023 | $339,315 | -28.9% | 16,915 | 0.0% | 0.02% | -25.0% |
| Q2 2023 | $477,173 | +64.0% | 16,915 | 0.0% | 0.02% | +53.8% |
| Q1 2023 | $290,938 | -14.6% | 16,915 | 0.0% | 0.01% | -18.8% |
| Q4 2022 | $340,668 | -6.9% | 16,915 | 0.0% | 0.02% | -15.8% |
| Q3 2022 | $366,000 | – | 16,915 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 187,143 | $765,415 | 25.27% |
| Decheng Capital LLC | 3,070,442 | $12,558,107 | 3.85% |
| MPM BioImpact LLC | 1,450,000 | $5,930,500 | 0.92% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $3,932,478 | 0.80% |
| Eventide Asset Management | 8,547,896 | $34,960,895 | 0.60% |
| 5AM Venture Management, LLC | 490,000 | $2,004,100 | 0.45% |
| Matrix Capital Management Company, LP | 13,959,973 | $57,096,290 | 0.44% |
| Values First Advisors, Inc. | 74,925 | $306,443 | 0.18% |
| Boxer Capital, LLC | 450,000 | $1,840,500 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 255,201 | $1,044 | 0.07% |